99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2349-2353

  Bakker, M ^c   Van Der Graaf, W T A ^c   Piers, D A ^c   Franssen, E J F ^c   Groen, H J M ^c   Smit, E F ^c   Kool, W ^c   Hollema, H ^c   Muller E A ^a   De Vries, E G E ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NONE

Author keywords

99mTc Sestamibi; Drug resistance; Imaging; PSC 833

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; VALSPODAR; CYCLOSPORIN DERIVATIVE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR SCINTISCANNING; BONE TUMOR; CHONDROSARCOMA; DRUG RESISTANCE; KIDNEY CARCINOMA; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; NEOPLASM; SARCOMA; SCINTISCANNING;

ADMINISTRATION, ORAL; ADULT; AGED; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CHONDROSARCOMA; CYCLOSPORINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; SARCOMA; TECHNETIUM TC 99M SESTAMIBI;

EID: 0032586895     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Goldie JH and Coldman AJ: The genetic origin of drug-resistance in neoplasms: application for systemic therapy. Cancer Res 44: 3643-3653, 1984.
2. Moscow JA and Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988.
3. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J and Ling V: Amplification of P-glycoprotein in multidrug resistant mammalian cell lines. Nature 316: 817-819, 1985.
4. Krishnamachary N and Center MS: The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 53: 3658-3661, 1993.
5. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
6. McLeod HL: Clinical reversal of the multidrug resistance phenotype: true tumor modulation or pharmacokinetic interaction? Eur J Cancer 30A: 2039-2041, 1994.
7. 99m-hexakis 2-methoxy isobutylisonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30: 301-311, 1989.
8. 99m-hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 14: 333-340, 1989.
9. 99m methoxyisobutylisonitrile. Eur J Nucl Med 20: 249-254, 1993.
10. 99m methoxyisobutylisonitrile localizes an ectopic ACTH-producing tumour: case report and review of the literature. Eur J Nucl Med 21: 582-586, 1994.
11. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA and Croop JM: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 53: 977-984, 1993.
12. 99m-sestamibi. J Nucl Med 35: 501-515, 1994.
13. Abdel-Dayem HM, Scott A, Macapinlac H and Larson S: Tracer imaging in lung cancer. Eur J Nucl Med 21: 81, 1994.
14. 99mTc-sestamibi. J Nucl Med 140P: 558, 1993.
15. 99mTc-Sestamibi accumulation in P-gp positive and MRP positive cell lines. Proc Am Assoc Cancer Res 36: #2132, 1995.
16. Hausdorff J, Fisher GA, Halsey J, Collins HL, Lum BL, Brophy NA, Duran GE, Nix D, Pearce T and Sikic BI: A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 14: 181, 1995.
17. Collins HL, Fisher GA, Hausdorff J, Lum BL, Pearce T, Halsey J and Sikic BI: Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator. Proc Am Soc Clin Oncol 14: 181, 1995.
18. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
19. Van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, Aalders JG and De Vries EGE: The value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2 and pS3 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78, 1995.
20. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR and Wittes RE: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13: 1985-1994, 1995.
21. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J and Sikic BI: Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994.
22. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Löwenberg B and Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259, 1992.
23. Van der Graaf WTA, Buter J, De Vries EGE, Willemse PHB, Sleijfer DTh and Mulder NH: High dose oral amiodarone added to doxorubicin and vindesine for overcoming multidrug resistance in solid tumors. Ann Oncol 5: 659-663, 1994.